[Skip to Content]
[Skip to Content Landing]
Citations 0
October 20, 1999

Incorrect Information

JAMA. 1999;282(15):1425. doi:10.1001/jama.282.15.1425

In the Medical News & Perspectives article entitled "FDA Weighs Communicating Drug-Related Risk to Patients" published in the August 11, 1999, issue of THE JOURNAL (1999;282:515), the words "troglitazone (Rezulin, used for type 2 diabetes)" should be deleted. No written informed consent has been recommended or advised in connection with the prescription of this drug.